Delivery outcome after maternal use of drugs for migraine: A register study in Sweden

Drug Safety

Volumn 34, Issue 8, 2011, Pages 691-703

  Klln, Bengt ^a   Nilsson, Emma ^b   Otterblad Olausson, Petra ^b  

^a UNIVERSITY OF LUND   (Sweden)

^b NATIONAL BOARD OF HEALTH AND WELFARE   (Sweden)

Author keywords

Almotriptan; Congenital abnormalities; Dihydroergotamine mesilate; Eletriptan; Ergotamines; Lisuride; Methysergide; Migraine; Naratriptan; Pizotifen; Pregnancy; Rizatriptan; Sumatriptan; Tryptamines; Zolmitriptan

Indexed keywords

ALMOTRIPTAN; ANALGESIC AGENT; ANTIBIOTIC AGENT; ANTICONVULSIVE AGENT; ANTIDEPRESSANT AGENT; ANTIHISTAMINIC AGENT; ANTIMIGRAINE AGENT; ATYPICAL ANTIPSYCHOTIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CORTICOSTEROID; DIHYDROERGOTAMINE; ELETRIPTAN; ERGOT DERIVATIVE; ERGOTAMINE; FOLIC ACID; GESTAGEN; HYPNOTIC AGENT; LISURIDE; METHYSERGIDE; NARATRIPTAN; NONSTEROID ANTIINFLAMMATORY AGENT; OPIATE; ORAL CONTRACEPTIVE AGENT; PIZOTIFEN; RIZATRIPTAN; SEDATIVE AGENT; SUMATRIPTAN; TRIPTAN DERIVATIVE; UNINDEXED DRUG; ZOLMITRIPTAN;

ADULT; ANUS ATRESIA; ARTICLE; BIRTH WEIGHT; BODY MASS; CARDIOVASCULAR DISEASE; CENTRAL NERVOUS SYSTEM MALFORMATION; CHROMOSOME ABERRATION; CONGENITAL MALFORMATION; CONTROLLED STUDY; CRANIOFACIAL SYNOSTOSIS; DELIVERY; DRUG EXPOSURE; EAR MALFORMATION; ESOPHAGUS ATRESIA; EYE MALFORMATION; FEMALE; GESTATIONAL AGE; HIP SUBLUXATION; HUMAN; HYPOSPADIAS; INFANT; INTESTINE ATRESIA; KIDNEY MALFORMATION; MALE; MIDWIFE; MIGRAINE; NEURAL TUBE DEFECT; NEWBORN MORBIDITY; NEWBORN MORTALITY; OROFACIAL CLEFT; PARITY; PREECLAMPSIA; PREGNANCY; PREGNANCY COMPLICATION; PREGNANCY OUTCOME; PREMATURE LABOR; PRENATAL CARE; PRIORITY JOURNAL; PYLORUS STENOSIS; REGISTER; SPONTANEOUS ABORTION; STILLBIRTH; SWEDEN; TERATOGENICITY;

ADOLESCENT; ADRENERGIC ALPHA-ANTAGONISTS; ADULT; FEMALE; HUMANS; INFANT, NEWBORN; MALE; MIDDLE AGED; MIGRAINE DISORDERS; PREGNANCY; PREGNANCY COMPLICATIONS; PREGNANCY OUTCOME; PRENATAL EXPOSURE DELAYED EFFECTS; REGISTRIES; RISK; SEROTONIN ANTAGONISTS; SEROTONIN RECEPTOR AGONISTS; SWEDEN; YOUNG ADULT;

EID: 79960375737     PISSN: 01145916     EISSN: 11791942     Source Type: Journal    
DOI: 10.2165/11590370-000000000-00000     Document Type: Article

References (22)

1. Pfaffenrath V, Rehm M. Migraine in pregnancy: what are the safest treatment options? Drug Saf 1998; 19: 383-8 (Pubitemid 28505196)
2. Fox AW, Chambers CD, Anderson PO, et al. Evidencebased assessment of pregnancy outcome after sumatriptan exposure. Headache 2002; 42: 8-15 (Pubitemid 34136605)
3. Fox AW. Revised estimate for probability of successful outcome of pregnancy after sumatriptan exposure [letter]. Headache 2004; 44: 842-3 (Pubitemid 39310981)
4. Cunnington M, Ephross S, Churchill P. The safety of sumatriptan and naratriptan in pregnancy: what have we learned? Headache 2009; 49: 1414-22
5. Nezvalová -Henriksen K, Spigset O, Nordeng H. Triptan exposure during pregnancy and the risk of major congenital malformations and adverse pregnancy outcomes: results from the Norwegian Mother and Child Cohort Study. Headache 2010; 50: 563-75
6. Heinonen OP, Sloane D, Shapiro A. Birth defects and drugs in pregnancy. Littleton (MA): Publishing Sciences Group, Inc., 1977
7. Källén B, Lygner P-E. Delivery outcome in women who used drugs for migraine during pregnancy with special reference to sumatriptan. Headache 2001, 41: 351-6 (Pubitemid 32372865)
8. Bá nhidy F, Puhó E, Czeizel AE. A possible dose-dependent teratogenic effect of ergotamine [letter]. Reprod Toxicol 2006, 22:551-2 (Pubitemid 44344448)
9. Bá nhidy F, A ́ rcs N, Horvá th-Puhó E, et al. Maternal severe migraine and risk of congenital limb deficiencies. Birth Defects Res Part A Clin Mol Teratol 2006, 76:592-601
10. Bá nhidy F, A ́ rcs N, Horvá th-Puhó E, et al. Pregnancy complications and delivery outcomes in pregnant women with severe migraine. Eur J Obstet Gynecol Reprod Biol 2006, 134:157-63
11. Bá nhidy F, A ́ cs N, Puhó E, et al. Ergotamine treatment during pregnancy and a higher rate of low birthweight and preterm birth. Br J Pharmacol 2007, 64:510-6
12. Graham Jr. JM, Marin-Madilla M, Hoefnagel D. Jejunal atresia associated with Cafergot ingestion during pregnancy. Clin Pediatr (Phila) 1983; 22: 226-8 (Pubitemid 13153058)
13. Barkovitch AJ, Rowley H, Bollen A. Correlation of prenatal events with the development of polymicrogyria. AJNR Am J Neuroradiol 1995; 16: 822-7
14. Smets K, Zecic A, Willems J. Ergotamine as a possible cause of Möbius sequence: additional clinical observation. J Child Neurol 2004; 19: 398 (Pubitemid 38867957)
15. Källén B. Drugs during pregnancy. New York: Nova Science Publishers, 2009
16. National Board of Health and Welfare, Centre for Epidemiology. The Swedish Medical Birth Register: a summary of content and quality [online]. Available from URL: http://www.socialstyrelsen.se/Publikationer2003/2003-112-3 [Accessed 2010 May 12]
17. Källén B, Otterblad Olausson P. Monitoring of maternal drug use and infant congenital malformations: does loratadine cause hypospadias? Int J Risk Safety Med 2001; 14: 115-9 (Pubitemid 35024885)
18. Wettermark B, Hammar N, Fored CM, et al. The new Swedish Prescribed Drug Register: opportunities for pharmacoepidemiological research and experience from the first six months. Pharmacoepidemiol Drug Saf 2007; 16: 726-35 (Pubitemid 47180362)
19. National Board of Health and Welfare, Centre for Epidemiology. Registration of congenital malformations in Swedish health registers [online]. Available from URL: http://www.socialstyrelsen.se/Publikationer2004/2004-112-1 [Accessed 2010 May 12]
20. Källén B. A birth weight for gestational age standard based on data in the Swedish medical birth registry 1985-1989. Eur J Epidemiol 1995; 11: 601-6
21. Torelli P, Allais G, Marizoni GG. Clinical review of headache in pregnancy. Neurol Sci 2010; 31, Suppl. 1: S55-8
22. Tietjen GE, Herial NA, Hardgrove J, et al. Migraine comorbidity constellations. Headache 2007; 47: 857-65 (Pubitemid 46944390)